Human immunodeficiency virus type 1 protease inhibitor attenuates Candida albicans virulence properties in vitro

被引:49
|
作者
Gruber, A
Speth, C
Lukasser-Vogl, E
Zangerle, R
Borg-von Zepelin, M
Dierich, MP
Würzner, R
机构
[1] Univ Innsbruck, Ludwig Boltzman Inst AIDS Forsch, A-6020 Innsbruck, Austria
[2] Univ Innsbruck, Inst Dermatol & Venereol, A-6020 Innsbruck, Austria
[3] Univ Gottingen, Inst Hyg, D-3400 Gottingen, Germany
来源
IMMUNOPHARMACOLOGY | 1999年 / 41卷 / 03期
基金
奥地利科学基金会;
关键词
Candida albicans; Indinavir; HIV-1;
D O I
10.1016/S0162-3109(99)00035-1
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The putative virulence factor secreted aspartyl proteinase (SAP) of Candida albicans and the human immunodeficiency virus type 1 (HIV-1) protease both belong to the aspartyl proteinase family. The present study demonstrates that the HIV-1 protease inhibitor Indinavir is a weak but specific inhibitor of SAP. In addition, Indinavir reduces the amount of cell bound as well as released SAP antigen from C. albicans. Furthermore, viability and growth of C. albicans are markedly reduced by Indinavir, These findings indicate that HIV-1 protease inhibitors may possess antifungal activity and we speculate that in vivo SAP inhibition may add to the resolution of mucosal candidiasis in HIV-1 infected subjects. (C) 1999 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:227 / 234
页数:8
相关论文
共 50 条
  • [1] Dissimilar attenuation of Candida albicans virulence properties by human immunodeficiency virus type 1 protease inhibitors
    Gruber, A
    Berlit, J
    Speth, C
    Lass-Florl, C
    Kofler, G
    Nagl, M
    Zepelin, MB
    Dierich, MP
    Wurzner, R
    IMMUNOBIOLOGY, 1999, 201 (01) : 133 - 144
  • [2] Antiviral properties of palinavir, a potent inhibitor of the human immunodeficiency virus type 1 protease
    Lamarre, D
    Croteau, G
    Wardrop, E
    Bourgon, L
    Thibeault, D
    Clouette, C
    Vaillancourt, M
    Cohen, E
    Pargellis, C
    Yoakim, C
    Anderson, P
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (05) : 965 - 971
  • [3] Human immunodeficiency virus type 1 Tat binds to Candida albicans, inducing hyphae but augmenting phagocytosis in vitro
    Gruber, A
    Lell, CP
    Speth, C
    Stoiber, H
    Lass-Flörl, C
    Sonneborn, A
    Ernst, JF
    Dierich, MP
    Würzner, R
    IMMUNOLOGY, 2001, 104 (04) : 455 - 461
  • [4] Human immunodeficiency virus type 1 gp160 and gp41 binding to Candida albicans selectively enhances candidal virulence in vitro
    Gruber, A
    Lukasser-Vogl, E
    Borg-von Zepelin, M
    Dierich, MP
    Würzner, R
    JOURNAL OF INFECTIOUS DISEASES, 1998, 177 (04): : 1057 - 1063
  • [5] Amprenavir: A new human immunodeficiency virus type 1 protease inhibitor
    Fung, HB
    Kirschenbaum, HL
    Hameed, R
    CLINICAL THERAPEUTICS, 2000, 22 (05) : 549 - 572
  • [6] In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632
    Gong, YF
    Robinson, BS
    Rose, RE
    Deminie, C
    Spicer, TP
    Stock, D
    Colonno, RJ
    Lin, PF
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (09) : 2319 - 2326
  • [7] Estimate of the frequency of human immunodeficiency virus type 1 protease inhibitor resistance within unselected virus populations in vitro
    Tucker, SP
    Stiebel, TR
    Potts, KE
    Smidt, ML
    Bryant, ML
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (02) : 478 - 480
  • [8] In vitro activity of a non-conventional (folding) protease inhibitor on human immunodeficiency virus type 1 replication
    Lo Cicero, M.
    Laface, A. E.
    Ferramosca, S.
    Sirianni, F.
    Cesana, E.
    Provasi, D.
    Tiana, G.
    Galli, M.
    Moroni, M.
    Clivio, A.
    Broglia, R. A.
    Rusconi, S.
    ANTIVIRAL THERAPY, 2007, 12 (05) : S19 - S19
  • [9] In vitro activity of a non-conventional (folding) protease inhibitor on human immunodeficiency virus type 1 replication
    Lo Cicero, M.
    Laface, A. E.
    Ferramosca, S.
    Sirianni, F.
    Cesana, E.
    Provasi, D.
    Tiana, G.
    Galli, M.
    Moroni, M.
    Clivio, A.
    Broglia, R. A.
    Rusconi, S.
    ANTIVIRAL THERAPY, 2007, 12 : S19 - S19
  • [10] Interaction of serotonin with Candida albicans selectively attenuates fungal virulence in vitro
    Mayr, A
    Hinterberger, G
    Dierich, MP
    Lass-Flörl, C
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2005, 26 (04) : 335 - 337